Friday, February 29, 2008
Real news in Real Time! National and international updates on all products by leading agencies such as Dow Jones, Capital Markets, Commodities Control and more.


Equity News
Feb 28 2008 9:33AM
Dabur Pharma in talks for possible sale - report

MUMBAI, Feb 28 (Reuters) - Dabur Pharma Ltd <DABR.BO>, a maker of anti-cancer drugs, is in talks with a German drug company for a partnership or a possible sale, the Economic Times newspaper said on Thursday quoting anonymous sources.

The German firm was not named by the paper.

"There is no move to induct any partner," the paper quoted Dabur's chief executive officer, Ajay Vij as saying. "We are in touch with many companies across the globe for hundreds of things, but this is pure speculation".

The sale or partnership was one of several options that Dabur was considering, including inducting a private equity or a strategic investor and a strategic alliance with a foreign company, the paper said, citing an anonymous industry source.

Last year, Dabur group firm Dabur Pharma sold its non-oncology drugs business to Alembic Ltd <ALMC.BO>, as part of its strategy to focus completely on cancer treatment drugs. (Reporting by Bharghavi Nagaraju; Editing by Ramya Venugopal) (([email protected]; +91 22 6636 9059; Reuters Messaging: [email protected])) Keywords: DABUR/SALE

  Source:   

Back
 
 
News
 
Research
 
Markets
 
Knowledge Center
 
Charting
 
Customer Service
 
Contact Us
 
Site Map
 

SEBI | BSE | NSE
Terms & Conditions | Disclaimer | Online Privacy | Trouble Logging in
Copyright© 2007. All rights Reserved. Reliance Money Limited
Equities: Trading through Reliance Securities Limited | NSE SEBI Registration Number Capital Market :- INB 231234833 | BSE SEBI
Registration Number Capital Market :- INB 011234839 | NSE SEBI Registration Number Derivatives :- INF 231234833 Commodities : Trading through Reliance Commodities Limited | MCX member code: 29030 | NCDEX member code: NCDEX-CO-05-00647|
NMCE member code: CL0120 Mutual Funds : Reliance Securities Limited | AMFI ARN No.29889
In case of any grievances please write to [email protected]
In case of any queries/ complaints with respect to stock broking transactions executed on this website or pertaining account opening, Pl.address your correspondence to Reliance Securities Limited.